Souza M, Al-Sharif L, Diaz I, et al. Representation of sex, race and ethnicity in mash randomised controlled trials: a systematic review and meta-analysis. Liver Int . 2025;45(4):e70029. doi:10. ...

Their results identified distinguishable lipid metabolites involved in metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH, adding to an emerging body of lipidomic and ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

LEXINGTON, Mass., February 26, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be worthwhile targets for new MASH therapies. The scientists published their work ...

Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US – its fourth bolt-on deal of 2021. South San Francisco-based Amunix specialises ...

S. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...

The global burden of cervical cancer is highest in low- and middle-income countries (LMICs). Women living with HIV infection are particularly impacted by cervical cancer despite availability and ...

U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024 ...

After hours: March 21 at 7:46:15 PM EDT Loading Chart for AIM ...